Preliminary 2025 thyroid testing revenue grew 21% over prior year Initial 2026 guidance of 16% growth in thyroid testing revenue All preferred stock converted to common stock Debt-free...
PARSIPPANY, NJ, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”) today announced that it has fully repaid its outstanding term loan...
● Q3 Revenue of $8.8 million ● Q3 Cash Collections of $10.0 million ● Q3 Thyroid test volume up 12% year-over-year to record levels ● Q3 Thyroid revenue...
Highlights Independent institutional experience shows archival cytology slides enabled successful molecular results in cases previously insufficient for testing by another commercially available molecular...
● Q2 Revenue of $9.2 million ● Q2 Cash Collections of $10.8 million ● Q2 Thyroid test volume up 16% year-over-year to record levels ● Q2 Thyroid revenue...